The increase in oral oncolytics has fueled an increase in physician dispensing of drugs either from the office or from a pharmacy owned by the practice or hospital, as allowed by state laws. Direct dispensing enables physicians to more comprehensively manage their patients’ medical and therapeutic needs and provides an extra revenue stream. However, some managed care organizations (MCOs) are concerned that physician dispensing diverts prescriptions from their specialty pharmacy or from their pharmacy benefit manager’s contracted specialty pharmacy. Understanding physician dispensing and its effect on payer reimbursement and on oncologists’ and urologists’ prescribing habits is essential to creating a sound market-access strategy for drugs to treat prostate cancer and other cancers with oral options.
Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so that clients can build their market access strategy and optimize their brand positioning.
KEY DRUGS COVERED
Erleada, Jevtana, Provenge, Xofigo, Xtandi, Zytiga, darolutamide